Nov. 3 at 4:30 p.m. EST

IRVINE, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) — Skyworks Solutions, Inc. (Nasdaq: SWKS), a leading developer, manufacturer and provider of analog and mixed-signal semiconductors and solutions will host a conference call with analysts to discuss its fourth quarter fiscal 2026 results and business outlook on Nov. 3, 2026, at 4:30 p.m. EST.

After the close of the market on Nov. 3, and prior to the conference call, Skyworks will issue a copy of the earnings press release via GlobeNewswire. The press release may also be viewed on Skyworks’ website at www.skyworksinc.com/investors.

To listen to the conference call, please visit the investor relations section of Skyworks’ website at https://investors.skyworksinc.com/events-presentations. Playback of the conference call will be available on Skyworks’ website at www.skyworksinc.com/investors beginning at 9 p.m. EST on Nov. 3. Additionally, a transcript of the company’s prepared remarks will be made available on our website promptly after their conclusion during the call.

About Skyworks
Skyworks® is a global leader in high-performance RF, precision timing, power management and mixed-signal solutions that power the intelligent, connected world. Through deep engineering expertise, Skyworks helps customers address rising complexity and deliver seamless connectivity across smartphones, vehicles, networks and critical infrastructure.

From defense and aerospace systems to the connected edge, AI infrastructure and next-generation automotive platforms, Skyworks provides the essential technologies that connect, synchronize and power physical AI, as intelligence moves out of the data center and into the real world. Harnessing decades of technical leadership and trusted partnerships across the technology ecosystem, Skyworks helps the world’s leading innovators bring next-generation products and services to market.

Skyworks is a member of the S&P 500® market index (Nasdaq: SWKS). For more information, please visit www.skyworks.com.

Safe Harbor Statement
Any forward-looking statements contained in this press release are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include without limitation information relating to future events, results and expectations of Skyworks. Forward-looking statements can often be identified by words such as “anticipates,” “expects,” “forecasts,” “intends,” “believes,” “plans,” “may,” “will” or “continue,” and similar expressions and variations or negatives of these words. Actual events and/or results may differ materially and adversely from such forward-looking statements as a result of certain risks and uncertainties, including those identified in the “Risk Factors” section of Skyworks’ most recent Annual Report on Form 10-K (and/or Quarterly Report on Form 10-Q) as filed with the Securities and Exchange Commission (“SEC”). Copies of Skyworks’ SEC filings can be obtained, free of charge, on Skyworks’ website (www.skyworksinc.com) or at the SEC’s website (www.sec.gov). Any forward-looking statements contained in this press release are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

Note to Editors: Skyworks and the Skyworks symbol are trademarks or registered trademarks of Skyworks Solutions, Inc., or its subsidiaries in the United States and other countries. Third-party brands and names are for identification purposes only and are the property of their respective owners.

Media Relations:        
Constance Griffiths
(949) 230-4867        
Constance.Griffiths@skyworksinc.com
Investor Relations:
Raji Gill
(949) 508-0973
Raji.Gill@skyworksinc.com        

New collaboration will bring Capitalization Table data to FactSet Workstation, strengthening and expanding its private markets offering for investment professionals

NORWALK, Conn., Oct. 20, 2026 (GLOBE NEWSWIRE) — FactSet, a leading global intelligence and AI solutions provider to the financial markets, has entered into a partnership with Nasdaq Private Market (NPM), a leading provider of liquidity, capital and investment solutions for private companies and investors, to integrate Capitalization (Cap) Table data into its platform. The intelligence sourced from NPM is expected to support more informed due diligence, valuation analysis, and deal sourcing – areas where reliable, structured data has historically been difficult to obtain.

The partnership comes at a particularly relevant moment. While private markets have grown significantly over the past decade, transparency, reporting standards, and data-sharing practices have struggled to keep pace. As investment professionals across all firm types are allocating more capital to private assets, the need for accurate, structured private markets data has grown sharply.

FactSet’s collaboration with NPM directly addresses this need. The integrated solution will give investment professionals a deeper insight into private company ownership structures and how financing transactions, such as new funding rounds, secondary sales, and dilutive events, affect ownership stakes and capital structure over time.

Critically, the Cap Table data sourced through NPM is supported by verifiable, auditable documentation and filings, rather than relying solely on modelled ownership estimates. This will provide financial and advisory firms with a higher degree of confidence in the data underpinning their investment and dealmaking workflows.

The NPM data also complements the private-company, funding, deal, and M&A data FactSet already provides. This enables clients to develop a more complete and connected view of private-market activity, spanning a company’s early funding history through to its current ownership and capital structure.

“Private markets have grown significantly, but the underlying ownership data hasn’t kept pace. As a result, firms have largely relied on modelled estimates rather than source documents. As an active secondary trading venue and private company share settlement engine, Nasdaq Private Market operates differently, working directly with the legal documentation that underpins private company ownership. The unique access to high-quality source data forms the basis of our partnership. The agreement also reflects FactSet’s ongoing commitment to expanding our private markets capabilities and ensuring clients have access to comprehensive, high-quality data across both public and private markets, all within a single platform.” – said Eric Weitzman, Senior Vice President, Senior Director of Data Partnerships at FactSet.

“Cap table data and in particular, share-class level information, is fundamental to how investment professionals evaluate private company investment opportunities and potential outcomes, and we are pleased to be working with FactSet to make this data more accessible to the market,” – said James Brooks, Chief Strategy Officer at Nasdaq Private Market.

The partnership reflects FactSet’s continued investment in private markets data capabilities and commitment to provide a top-grade trusted financial intelligence for all firm types across public and private markets within a unified ecosystem.

About FactSet

FactSet (NYSE:FDS | NASDAQ:FDS) supercharges financial intelligence, offering enterprise data and information solutions that help our clients maximize their potential. Our cutting-edge digital platform seamlessly integrates proprietary financial data, client datasets, third-party sources, and flexible technology to deliver tailored solutions across the buyside, sell side, wealth management, private equity, and corporate sectors. With over 48 years of expertise, a presence in 20 countries, and extensive multi-asset class coverage, we leverage advanced data connectivity alongside AI and next-generation tools to streamline workflows, drive productivity, and enable smarter, faster decision-making. Serving more than 9,200 global clients and over 260,000 individual users, FactSet is a member of the S&P 500 dedicated to innovation and long-term client success.
Learn more at www.factset.com and follow us on X and LinkedIn.

About Nasdaq Private Market

Nasdaq Private Market is a leading provider of liquidity, capital, and investment solutions for private companies, employees, and investors. The company is focused on building modern infrastructure for the private market ecosystem, including technology for company-sponsored liquidity events, a settlement engine for private shares, a marketplace for buying and selling private company stock and funds, and data and intelligence on the private market. Nasdaq Private Market also helps connect private companies to capital through primary fundraising and capital introduction. For more information, visit nasdaqprivatemarket.com.

FactSet Investor Relations:
Kevin Toomey
+1.212.209.5259
Kevin.toomey@factset.com

FactSet Media Relations:
Alexandra Shevchenko
Oleksandra.shevchenko@factset.com

NPM Media Relations:
Samantha Tortora
press@npm.com

Calibration Guidelines bring recommendations from leading providers into repair and claims workflows to support proper and consistent vehicle repairs

CHICAGO, Oct. 20, 2026 (GLOBE NEWSWIRE) — As advanced driver assistance systems (ADAS) become more common and complex, repairers and insurers need trusted calibration guidance at the point of decision. CCC Intelligent Solutions Inc. (CCC), a leading SaaS and AI platform powering the insurance and repair economy, today announced Calibration Guidelines, a new capability that brings recommendations from leading providers directly into existing estimating workflows.

“The growing complexity of today’s vehicles is raising the stakes for every participant in the repair ecosystem,” said Dan Risley, vice president, Automotive Services Group for CCC. “Supporting safe, proper, and consistent repairs requires collaboration across repairers, insurers, automakers, diagnostics providers, and technology partners. CCC is helping make trusted calibration guidance easier to access and apply as repair and claims decisions are being made.”

Industry stakeholders, including leading repair associations and consumer advocacy groups, have increasingly identified ADAS calibrations as one of the collision repair industry’s most pressing issues, citing the need for easier access to trusted repair guidance.

“ADAS represents one of the most significant technological changes our industry has ever faced,” said Erick Bickett, Director, PACE Calibration Centers. “The pace and magnitude of this change demand collaboration across the entire industry. We appreciate CCC’s leadership in making calibration guidance more accessible at the point where critical repair decisions are made and for their work as part of CIECA’s ADAS Calibration Committee. Together, these efforts are important steps toward greater transparency and proper repairers.”

CCC’s Calibration Guidelines sources recommendations, informed by vehicle manufacturers’ repair and calibration requirements, from leading calibration and diagnostics providers. Current participants include asTech (via adasThink), Azimuth, Opus (via ADAS Map Pro), Kinetic and REVV.

“No single stakeholder can solve this challenge alone,” Risley added. “The industry’s continued focus on ADAS calibration reflects a shared commitment to consumers, safer roadways, and the proper repair of increasingly sophisticated vehicles. CCC is proud to support those efforts by helping connect trusted information with the people who need it.”

Calibration Guidelines is available to all CCC ONE users at no additional cost from CCC. Customers with a contracted participating provider can access recommendations through the Diagnostics button in CCC ONE; insurers using Advanced or Intelligent Estimating in APEX can also access the capability.

Visit cccis.com/diagnostics to learn more.

About CCC
CCC Intelligent Solutions Holdings Inc. (NASDAQ: CCC) is a leading SaaS and AI platform powering the multi-trillion-dollar insurance and repair economy. CCC connects more than 35,000 businesses, including insurers, repairers, automakers and parts suppliers, through the workflows where claims and repair decisions are made every day. With AI built into those workflows for over a decade and informed by more than 40 years of industry data, CCC helps customers manage growing complexity and move work forward with confidence. Through purposeful innovation and the strength of its network, CCC helps keep people’s lives moving forward when it matters most. Learn more about CCC at www.cccis.com.

Special Note Regarding Forward-Looking Statements 

This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements regarding future use and performance of CCC’s digital solutions. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, competition, including technological advances and new products marketed by competitors; changes to applicable laws and regulations; and other risks and uncertainties, including those included under the header “Risk Factors” in CCC’s filings with the Securities and Exchange Commission (“SEC”), including the Form 10-K filed February 24, 2026, which can be obtained, without charge, at the SEC’s website (www.sec.gov). The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. 

CCC Media Contact: Michelle Hellyar
mhellyar@cccis.com | 773.791.3675

WEST PALM BEACH, Fla., Oct. 20, 2026 (GLOBE NEWSWIRE) — Advanced Flower Capital Inc. (Nasdaq: AFCG) (“AFC”) today announced that it will release its financial results for the third quarter ended September 30, 2026, on Thursday, November 5, 2026, before market open. Management will review AFC’s financial results at 10:00 am ET via webcast available on the Investor Relations section of AFC’s website found here AFC — Investor Relations. Participants are also invited to access the conference call by registering in advance at this link. A replay will be available one hour after the event.

AFC distributes its earnings releases via its website and email lists. Those interested in receiving firm updates by email can sign up for them here.

About AFC

AFC (Nasdaq: AFCG) is a publicly traded business development company that provides flexible credit solutions to lower middle-market companies. The company primarily originates, structures, invests and manages direct senior debt investments, targeting companies generating annual EBITDA of $5 to $50 million. The company seeks to maximize risk-adjusted returns for its stockholders with an opportunistic approach across all industries. AFC is headquartered in West Palm Beach, Florida. For additional information regarding the company, please visit www.afcbdc.com.

Investor Relations Contacts

Robyn Tannenbaum // Will Rotatori
561-510-2293 // 561-510-6109
ir@afcbdc.com

Media Contact

Jim Velgot
561-510-1416
ir@afcbdc.com

TAIPEI, Taiwan, and BOTHELL, Wash., Oct. 20, 2026 (GLOBE NEWSWIRE) — YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection and ophthalmologic innovations, today announced a strategic collaboration with EG BioMed Co., Ltd., a Taiwan registered company and an affiliate of YD Bio (“EG BioMed”), and digital health provider JoiiUp. The partnership integrates an AI Cancer Risk Assessment (the “Assessment”), jointly developed by YD Bio and EG BioMed, into JoiiUp’s JoiiSports app, expanding access to personalized health insights for corporate wellness programs and healthcare institutions.

Key Collaboration Highlights

  • Clinically Validated Data: The Assessment was developed in collaboration with three Taipei Medical University (TMU) affiliated hospitals and validated using over 1,200 clinical records.
  • Broad Immediate Reach: JoiiUp brings over 12 years of workplace health promotion experience, actively supporting the employee wellness programs of over 400 companies.
  • Non-Invasive Profiling: The tool utilizes an online health questionnaire and proprietary AI models mapped against medical literature to analyze demographic data, lifestyle habits, and family history across ten cancer types—requiring no blood draws or imaging.
  • Actionable Digital Integration: By leveraging Single Sign-On (SSO), users can seamlessly access the Assessment directly within the JoiiSports app to generate personalized risk reports and targeted lifestyle recommendations.

Strategic Market Integration

The integration will connect the Assessment with JoiiUp’s existing exercise, nutrition, and sleep management ecosystem. Initial deployment is expected to focus on JoiiUp’s existing corporate partner network, enabling employers to seamlessly add targeted cancer risk analysis to their employee health benefits. Following successful corporate implementation, the companies plan to expand the offering to healthcare institutions as a supplementary tool for patient education and consultation.

Management Perspectives

“A key to cancer prevention is understanding risk early and taking timely action,” said Dr. Ethan Shen, Chairman and CEO of YD Bio. “This Assessment is the first step in building a comprehensive cancer management pathway spanning risk assessment, early detection, and precision medicine. Through JoiiUp, we are bringing personalized risk analysis directly into everyday health management and supporting vital follow-up discussions with healthcare professionals.”

Dr. Ruo-Kai Lin, Professor at TMU and Chief of R&D at EG BioMed, noted: “Through questionnaires and personalized analysis, we hope to help users understand their risks and inform discussions with healthcare professionals. Partnering with JoiiUp makes this clinically validated information vastly more accessible.”

Important Regulatory Disclosure

The Assessment is a cancer risk-stratification and health guidance tool. It uses statistical and artificial intelligence methods applied to health information self-reported by the user. Its output does not represent the probability of developing cancer. It does not diagnose cancer and is not intended for cancer diagnosis, screening, early detection, disease prediction, or treatment decision-making; it cannot replace professional medical evaluation, diagnostic testing, or consultation with a qualified healthcare provider, and does not replace recommended cancer screening.

About JoiiUp

JoiiUp delivers smart health management and digital health services. Its JoiiSports app combines wearable devices, exercise and nutrition management, and AI health applications to build healthy lifestyles. The JoiiCare platform provides wellness activities and health management tools for over 400 corporate clients. For more information, visit www.joiiup.com.

About EG BioMed

EG BioMed is a biotechnology and clinical services company focused on advancing early cancer detection and diagnostic solutions. YD Bio entered into a Memorandum of Understanding to merge with EG BioMed in January 2026 and is advancing the transaction, which is anticipated to close in 2026, subject to customary closing conditions, regulatory approvals, and the finalization of definitive agreements.

About YD Bio Limited

YD Bio is a U.S.-anchored public biotechnology company building an integrated healthcare platform spanning regulated molecular diagnostics, clinical services, precision medicine, and life science commercialization. The Company operates DNA methylation–based oncology testing programs in the United States under a laboratory-developed test strategy and supports pharmaceutical and biotechnology partners through compliant life science distribution and clinical trial supply chain services. In addition, the Company maintains regulated ocular health commercialization operations and a consumer health distribution platform in Asia. For more information, visit ir.ydesgroup.com and follow the Company on Facebook, X, Threads, Instagram and LinkedIn.

Forward-looking statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions created by the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s plans, objectives and expectations for its business, strategy and operations; and the planned partnership with EG BioMed and JoiUpp, along with the associated integration of the Assessment into the JoiiSports app, the implementation approach, the anticipated commercial and strategic benefits of the partnership and related future expansion plans. Forward-looking statements are not guarantees of future performance and can be identified by words such as “aim,” “intend,” “seek,” “believe,” “designed to,” “expects,” “anticipates,” “plans,” “may,” “could,” “hope,” “will” and other similar expressions. Actual results may differ materially from those expressed or implied due to a variety of factors, including system integration and implementation challenges; corporate client requirements; consumer demand and market acceptance; competition; regulatory and labeling requirements in Taiwan and other jurisdictions; currency exchange rates; geopolitical tensions and macroeconomic conditions; and other risks and uncertainties described in YD Bio’s filings with the U.S. Securities and Exchange Commission. The Company cautions investors not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update any forward-looking statement, except as required by law, and encourages investors to review the risk factors in its Annual Report on Form 20-F and other SEC filings.

For investor and media inquiries, please contact:

YD Bio Limited
Investor Relations
Email: investor@ydesgroup.com

WFS Investor Relations Inc.
Email: services@wfsir.com
Phone: +1 628 283 9214

John Dawson CBE, Deborah Ramsdell and Bruce Wendel bring corporate development, commercialization, and regulatory experience to the Company as it advances PDS0301 toward Phase 3 trial in Metastatic Colorectal Cancer (mCRC) and PDS0101 toward potential partnerships

PRINCETON, N.J., Oct. 20, 2026 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the appointments of John Dawson CBE, Deborah Ramsdell, and Bruce Wendel to the Company’s Board of Directors (the “Board”), effective as of October 18, 2026. The appointments follow the resignations of Stephen Glover, Kamil Ali-Jackson, Esq., Gregory Freitag, J.D., CPA, and Otis Brawley, M.D., effective October 18, 2026.

“On behalf of the Board, I am delighted to welcome three such accomplished pharma industry executives to PDS Biotech,” said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech. “John, Deborah and Bruce have had extraordinarily distinguished careers, and bring deep experience in drug development, commercialization, regulatory affairs and partnership negotiations to our Board. We expect their perspectives to support the Company as we advance PDS0301 toward a Phase 3 trial in metastatic colorectal cancer and pursue our partnership strategy for PDS0101.”

Dr. Bedu-Addo added, “I also extend the Board’s thanks to Stephen, Kamil, Greg and Otis for their contributions to PDS Biotech in shaping the Company’s clinical development strategy. In particular, Otis’ distinguished oncology experience played an important role in shaping the Company’s clinical development strategy. We are grateful for their guidance and many contributions.”

The reconstituted Audit Committee comprises Mr. James Banaag (Chair), Mr. John Dawson and Mr. Bruce Wendel. The Compensation Committee comprises Dr. Patrick Soon-Shiong (Chair), Mr. James Banaag and Mr. John Dawson. The Nominating and Governance committee consists of Mr. Bruce Wendel (Chair), Ms. Deborah Ramsdell and Dr. Ilian Iliev.

About the New Directors

Mr. John A. Dawson CBE has served as Executive Chair of Virocell Therapeutics, a privately held cell and gene therapy company, since March 2023. Since January 2023, he has served as a non-executive director and chair of the audit and risk committee of Norgine, a privately held specialty pharmaceutical company, and since June 2022, he has served as a non-executive director of Chinese Specialty Pharma Ltd., a privately held specialty pharmaceutical company. From February 2022 to January 2024, Mr. Dawson served as a non-executive director, senior independent director and chair of the audit and remuneration committees of Ergomed plc. From August 2008 to January 2022, he served as Chief Executive Officer of Oxford Biomedica plc and remained a member of its board of directors until May 2022. During his tenure as CEO, he rejuvenated the company’s drug development and LentiVector platform, and elevated the company to a leading position in the world of cell and gene therapy. He secured deals with companies with Sanofi, Novartis, Orchard Therapeutics, Boehringer Ingelheim and Axovant with total value in excess of $1.75bn. From 1997 to 2007 Mr. Dawson was head of Europe for Cephalon. During his tenure at Cephalon he played multiple roles within the organization including CEO Pharmaceutical Operations Europe, Country Manager UK & Senior European Financial Director and European Financial Director. At Cephalon Mr. Dawson led several deals during which the market capitalization of the company grew from $150m to $1b. Mr. Dawson holds a B.Sc. (Hons) in Mathematics from the University of Swansea and is a member of the Institute of Chartered Accountants in England and Wales.

Ms. Deborah A. Ramsdell, a regulatory expert, brings more than 35 years of experience in leadership roles at early- and clinical-stage biotechnology companies, with broad regulatory expertise in drug development, including rare disease drug development. Over the course of her career, she has been responsible for the strategic design, leadership and operational oversight of multiple drug candidates in the fields of oncology, rare metabolic diseases, dermatology, pain, infectious diseases, transplantation, cardiology, renal diseases, and endocrinology. Between 2010 and 2018 she served as Executive Team/Board of Director member for four biotechnology companies that were sold to pharmaceutical/biotech companies for $350M – $1.1B. Since August 2026, Ms. Ramsdell has served as Chief Executive Officer of Pluvia Biotech, a privately held clinical-stage company developing a therapy for phenylketonuria. Since 1996, she has been the owner of CMS International, Inc., a healthcare consulting firm. From February 2021 to July 2024, she served as co-founder and Chief Executive Officer of Phoenicis Therapeutics, a privately held clinical-stage biotechnology company, and from January 2013 to May 2020, she served as President and Chief Executive Officer of Valerion Therapeutics, a privately held biotechnology company. Ms. Ramsdell holds a B.S. in Biology and M.Ed. in Special Education from Boston College.

Mr. Bruce Wendel has had several leading roles at top tier pharmaceutical and biotech companies. As EVP of Corporate Development at Bristol-Myers Squibb Company he led negotiations of M&A transactions, licensing and co-promotion deals and divestitures globally. From April 2018 to May 2019, he served as Chief Business Development Officer for ProMetic Biosciences Ltd., a pharmaceutical development company, and he also served as a director of ProMetic Biosciences Ltd. He also served as Chief Strategic Officer of Hepalink USA, the U.S. subsidiary of Shenzhen Hepalink Pharmaceutical Company, from July 2012 to July 2018 and as Chief Executive Officer of Scientific Protein Laboratories, LLC from December 2014 to June 2015. Prior to this, having served in roles of increasing responsibility at Abraxis BioScience, LLC, he was appointed Vice Chairman and Chief Executive Officer, overseeing the commercialization of Abraxane® and leading the negotiations that culminated in the acquisition of the company by Celgene Corporation in 2010. He was also Vice President of Business Development at IVAX Corporation, and at American Pharmaceutical Partners, Inc. From November 2020 to May 2025, he served on the board of directors of GT BioPharma, Inc., and from June 2016 through May 2021, he served on the board of directors of Verastem, Inc. He currently serves on the board of ImmunityBio. He earned a juris doctor degree from Georgetown University Law School, and a B.S. from Cornell University.

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to conduct clinical trials for PDS0301, PDS0101 (Versamune® HPV), PDS0103 (Versamune® MUC1) and other Versamune® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0301, PDS0101 (Versamune® HPV), PDS0103 (Versamune® MUC1) and other Versamune® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s or its partners’ ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding response rates, the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company’s ability to continue as a going concern; compliance with the rules and regulations of Nasdaq; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:
Mike Moyer
LifeSci Advisors
Phone +1 (617) 308-4306
Email: mmoyer@lifesciadvisors.com

Media Contact:
Jude Gorman / Kiki Torpey
Collected Strategies
PDS-CS@collectedstrategies.com

Work-in-progress image. Subject to change prior to launch.

Work-in-progress image. Subject to change prior to launch.
Work-in-progress image. Subject to change prior to launch.

Work-in-progress image. Subject to change prior to launch.

Work-in-progress image. Subject to change prior to launch.
Work-in-progress image. Subject to change prior to launch.

Work-in-progress image. Subject to change prior to launch.

Work-in-progress image. Subject to change prior to launch.
Work-in-progress image. Subject to change prior to launch.

Work-in-progress image. Subject to change prior to launch.

Work-in-progress image. Subject to change prior to launch.
Work-in-progress image. Subject to change prior to launch.

Work-in-progress image. Subject to change prior to launch.

Work-in-progress image. Subject to change prior to launch.
Work-in-progress image. Subject to change prior to launch.

Naples, Italy and Hamilton, Bermuda, Oct. 20, 2026 (GLOBE NEWSWIRE) — October 20, 2026 – The RoyaLand Company Ltd. (the “Company” or “RoyaLand”) (OTCQB: RLNDF), a Bermuda holding company focused on creating immersive, fantasy-based royalty-themed games and growing its Italian professional football club Savoia 1908 FC, today provided new details on Palazzo Chronicles, a free-to-play mobile game that blends match-3 puzzles with castle and garden building. Taking place in the fictional Contea di Lunalba in Piedmont during the reunification of Italy, the game follows Adelaide, heir to the county and castle of Count Lunalba, as she takes on the restoration of her family’s ruined home. The game is expected to launch on iOS and Android in Q4 2026.

Inherit a Ruin. Rebuild a Legacy.

Adelaide, granddaughter of Count Lunalba, arrives at the family castle after a long journey, a letter from her grandfather in hand. He has left her the county and the castle. What she finds is a ruin, picked clean by her cousin, Barone Enrico, and abandoned by nearly everyone who once lived there. Adelaide has one advantage: a gift she has kept hidden, the same one that saw her sent away as a child and can now help her bring the castle back.

A Household Worth Rebuilding

Around Adelaide gathers a household of unlikely allies: an old steward who nearly walked out, a maid who once served the lord of the castle, a knight bound by a sworn oath, and, of course, a stray cat. Beneath the dust sits a secret half a century old, and the one man who witnessed it has kept quiet ever since. Players will have to uncover the rest for themselves.


Work-in-progress image. Subject to change prior to launch.


Work-in-progress image. Subject to change prior to launch.


Work-in-progress image. Subject to change prior to launch.


Work-in-progress image. Subject to change prior to launch.


Work-in-progress image. Subject to change prior to launch.

Match, Combine, Rebuild

At its core, Palazzo Chronicles is a full match-3 puzzle game, with boosters and combos that reward clever gameplay. Those puzzles sit alongside a castle and garden decoration system that puts creative control in the player’s hands, from the great halls to the grounds outside. A cast of characters keeps the journey moving.

A Mystery in Many Chapters

The story unfolds across a series of chapters. Each one restores another part of the castle and deepens the mystery along the way. Restoring the castle is the heart of Adelaide’s inheritance, and the full story is waiting for players at launch.

A Setting Steeped in History

The Contea di Lunalba may be fictional, but the world around it is real. The game unfolds in Piedmont during the 19th-century movement that reunified Italy, marking an era of change and reinvention that makes a fitting backdrop for a story about rebuilding.

Palazzo Chronicles is supported by in-game advertising and will be available in Italian and English. Its features, content, and launch timing remain subject to change.

Where the Puzzle Meets the Story

“Match-3 is one of the most familiar and widely played formats in mobile gaming. Combining that with the concept of restoring a castle one room at a time happens to be a perfect fit for our royalty-themed mobile game series. In Palazzo Chronicles every cleared board puts a room back together, and every restored room gives Adelaide back a piece of her grandfather. The puzzle and the story advance on the same action. That was the premise we started from, and it is the whole reason the game works.”

  • Soheil Raissi, Chief Technology Officer of RoyaLand.  

About The RoyaLand Company Ltd.

The RoyaLand Company Ltd. is a Bermuda holding company focused on creating an online and offline immersive, fantasy-based royalty-themed game called TheRoyal.Land as well as mobile and other games, and ownership and growth of its Italian professional football club Savoia 1908 FC. The Company is actively focused on developing what it believes to be a novel, interactive and immersive game based on a player-empowered design. This game is expected to feature proprietary digital avatars and provide opportunities to players to earn in-game reward currency, build virtual land, and own their online assets while enhancing all of these features with premium incremental in-game content. Bridging the virtual video game world and terrestrial soccer, Savoia 1908 FC has also completed a tournament season for its eSports team competing in EA Sports FC™ online matches.

TheRoyal.Land and the management and development of Savoia 1908 FC are being conducted in collaboration with the Company’s founder and CEO Prince Emanuele Filiberto di Savoia — the grandson of the last King of Italy — as well as seven other royal families and families with legal, hereditary or historically based claims to royal positions in Russia, Albania, France, Bulgaria, Yugoslavia, Lesotho (Africa), and Mecklenburg (Germany). TheRoyal.Land is intended to integrate these families’ first-hand historical perspectives to deliver an authentic and unique past-meets-future entertainment experience.

CONTACT:
investors@theroyal.land
www.TheRoyal.Land

Attachments

Mount Logan Management LLC has signed a definitive agreement to succeed Alternative Fund Advisors, LLC as investment adviser to the AFA Asset Based Lending Fund, which will bring Mount Logan’s interval fund assets under management to approximately $460 million.

Once the transaction closes, the Fund will be renamed Mount Logan Asset Based Lending Fund and will continue its focus on asset-based and specialty finance investing. The Fund’s shareholders will gain access to a larger asset management platform and increased direct origination of lending opportunities.

Mount Logan currently expects the transaction will be immediately accretive to its FRE1 upon closing.

The transaction is expected to close in Q1 2027, subject to regulatory and shareholder approvals.

NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) — Mount Logan Capital Inc. (Nasdaq: MLCI) (“Mount Logan”) today announced that Mount Logan Management LLC, its wholly owned registered investment adviser (“MLM”), has entered into a definitive agreement to become the new investment adviser to the AFA Asset Based Lending Fund (“Fund”) (the “Transaction”). In connection with the Transaction, MLM and Alternative Fund Advisors, LLC (“AFA”), the Fund’s current investment adviser, have entered into an Asset Purchase Agreement (the “APA”) pursuant to which MLM will acquire certain business records, intellectual property, and goodwill of AFA related to the management of the Fund.

The Fund will be MLM’s second evergreen credit interval fund, complementing MLM’s Opportunistic Credit Interval Fund. Together, the two funds establish a scaled, differentiated product suite for the private wealth channel, spanning asset-based specialty finance and opportunistic corporate credit.

Upon closing, the Fund will be renamed Mount Logan Asset Based Lending Fund. It will continue to provide access to a broadly diversified range of asset-based lending and specialty finance credits. Fund shareholders are expected to benefit from MLM’s scale, resources and extensive in-house origination capability. The Fund manages approximately $230 million in assets from a wide range of investors, particularly those interested in diversifying their fixed income portfolios.

The Transaction will bring MLM’s combined interval fund assets to approximately $460 million. Mount Logan currently expects the Transaction will be immediately accretive to FRE upon closing.

Ted Goldthorpe, CEO of Mount Logan, said, “This is a significant milestone in the build-out of Mount Logan’s evergreen credit platform and reflects our continued discipline in acquiring permanent and semi-permanent capital vehicles. The Fund broadens MLM’s core products, extends our distribution reach in the private wealth channel, and is highly complementary to our Opportunistic Credit Interval Fund. It also provides a differentiated, institutionally managed asset-based lending strategy that leverages the credit sourcing and underwriting capabilities of the broader Mount Logan and BC Partners Credit platform.”

“We are excited about this next phase in the evolution of the AFA Asset Based Lending Fund,” said Marco Hanig, CEO of Alternative Fund Advisors. “We expect the resources and investment expertise of the Mount Logan platform to enhance the Fund’s strategy through direct origination alongside third-party origination channels. We look forward to partnering with Ted and the Mount Logan team in the Fund’s next phase of growth.”

About Mount Logan Capital Inc.
Mount Logan Capital Inc. (“MLCI”) is an integrated alternative asset management and insurance solutions firm focused on generating durable, fee-based revenue and long-term value creation. MLCI leverages differentiated investment strategies alongside permanent insurance capital to deliver attractive, risk-adjusted returns across market cycles.

Through its subsidiaries, MLM and Ability Insurance Company, MLCI manages and invests across private and public credit markets in North America and operates an insurance platform that provides long-duration liabilities to support its credit investment strategies. This integrated platform is designed to provide stable earnings, downside protection, and a low risk of principal impairment through the credit cycle.

As of June 30, 2026, MLCI had over $2 billion in assets under management.

About AFA Asset Based Lending Fund
The AFA Asset Based Lending Fund is an interval fund launched on June 30, 2021 that seeks high current income by investing in a diversified portfolio of asset-based loans across specialty finance, real estate, and other private credit niches. The Fund offers daily subscriptions at net asset value and conducts quarterly repurchase offers subject to a limit of 5% of the Fund’s net assets. As of September 30, 2026, the Fund had approximately $230 million in net assets across 650 underlying investments.

About Alternative Fund Advisors, LLC
Alternative Fund Advisors provides financial advisors and family offices with efficient and convenient access to private investments through interval funds.

Approvals and Timing
Additional details regarding the Transaction are available on a Current Report on Form 8-K that was filed by Mount Logan with the U.S. Securities and Exchange Commission (the “SEC”) at www.sec.gov. The Transaction has been unanimously approved by the AFA Asset Based Lending Fund’s board of trustees, as well as Mount Logan’s board of directors. The change in investment adviser and the new investment management agreement are subject to approval by a majority of the Fund’s shareholders, as well as customary regulatory approvals. The Fund intends to file a proxy statement with the SEC shortly following this announcement and thereafter commence the shareholder vote solicitation. Subject to the requisite approvals, closing is expected to occur in Q1 2027.

Advisors
Dechert LLP is serving as legal counsel to Mount Logan. Faegre Drinker Biddle & Reath LLP is serving as legal counsel to the AFA Asset Based Lending Fund and its Board of Trustees. Reitler Kailas & Rosenblatt LLP is serving as legal counsel and Berkshire Global Advisors is serving as financial advisor to AFA.

DISCLOSURES
Estimates and Assumptions
This press release includes unaudited financial and business projections. These projections, and their underlying assumptions, are inherently unpredictable and undue reliance should not be placed thereon.

These estimates reflect internal financial models that Mount Logan uses in connection with its strategic planning and are based on numerous variables and assumptions made by Mount Logan’s management with respect to industry performance, general business, economic, regulatory and financial conditions and other future events, as well as matters specific to Mount Logan’s businesses, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Mount Logan’s management. As a result, these estimates constitute forward-looking statements and are subject to many risks and uncertainties that could cause actual results to differ materially from these projections. Please carefully consider “Cautionary Statement Regarding Forward-Looking Statements” below. There can be no assurance that these estimates will be realized or that actual results will not be significantly different than projected.

The inclusion of these estimates in this press release should not be regarded as an indication that Mount Logan or any of its affiliates, advisors, officers, directors or representatives considered or considers such estimates to be necessarily predictive of actual future events, and these estimates should not be relied upon as such. The inclusion of these estimates herein should not be deemed an admission or representation by Mount Logan that its management views these estimates as material information.

Certain of the estimates and projections set forth herein may be considered non-GAAP financial measures, including FRE. There are limitations inherent in non-GAAP financial measures, because they exclude charges and credits that are required to be included by generally accepted accounting principles in the United States (“GAAP”). Non-GAAP measures should not be considered in isolation from, or as a substitute for, financial information presented in compliance with GAAP, and non-GAAP financial measures used by Mount Logan may not be comparable with similarly titled amounts used by other companies. No reconciliation of these non-GAAP measures was created or used in connection with preparing the estimates included herein.

Cautionary Statement Regarding Forward-Looking Statements
This press release, and oral statements made from time to time by representatives of Mount Logan, AFA or AFA Asset Based Lending Fund may contain statements of a forward-looking nature relating to future events within the meaning of applicable U.S. and Canadian securities laws. Forward-looking statements may be identified by words such as “anticipates,” “believes,” “could,” “continue,” “estimate,” “expects,” “intends,” “will,” “should,” “may,” “plan,” “predict,” “project,” “would,” “forecasts,” “seeks,” “future,” “proposes,” “target,” “goal,” “objective,” “outlook” and variations of these words or similar expressions (or the negative versions of such words or expressions). Forward-looking statements are not statements of historical fact and reflect Mount Logan’s or AFA’s current views about future events. Such forward-looking statements include, without limitation, statements about the expected timing and benefits of the transaction, the expected increase in FRE and accretive nature of the transaction between AFA and Mount Logan, future financial and operating results, Mount Logan’s or the Fund’s plans, objectives, expectations and intentions regarding our business strategy and plans, and other statements that are not historical facts, including but not limited to the inability to complete and recognize the anticipated benefits of the transaction on the anticipated timeline or at all, including as a result of a failure to obtain the required shareholder or regulatory approvals, changes in the Fund’s assets under management, purchase price adjustments, unexpected costs related to the transaction, future results of operations, projected cash flow and liquidity, business strategy, shareholder liquidity and the payment of dividends to shareholders of Mount Logan or the Fund, and other plans and objectives for future operations. No assurances can be given that the forward-looking statements contained in this press release will occur as projected, and actual results may differ materially from those projected. Forward-looking statements are based on current expectations, estimates and assumptions that involve a number of risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those projected. Forward-looking statements are based on the estimates and opinions of management at the time the statements are made. Readers should carefully review the statements set forth in the reports, which Mount Logan and the Fund have filed or will file from time to time with the SEC or on SEDAR+ and any risk factors contained in such reports, including the section titled “Risk Factors” in Mount Logan’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 19, 2026. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements.

Each of Mount Logan, AFA and the Fund does not undertake any obligation, and expressly disclaims any obligation, to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. Any discussion of past performance is not an indication of future results. Investing in financial markets involves a substantial degree of risk. Investors must be able to withstand a total loss of their investment. The information herein is believed to be reliable and has been obtained from sources believed to be reliable, but no representation or warranty is made, expressed or implied, with respect to the fairness, correctness, accuracy, reasonableness or completeness of the information and opinions. The information contained on the website of Mount Logan or the Fund is not incorporated by reference into this press release. Neither Mount Logan, AFA nor the Fund is responsible for the contents of third-party websites.

No Offer or Solicitation
This press release is not, and under no circumstances is it to be construed as, a prospectus or an advertisement and the communication of this release is not, and under no circumstances is it intended to be and does not constitute an offer to sell or the solicitation of an offer to purchase any securities in MLCI, the Fund, or in any fund or other investment vehicle in any jurisdiction pursuant to the proposed transactions or otherwise, nor is it intended to solicit a proxy from any shareholder of the Fund.

Additional Information and Where to Find It
Additional information regarding the proposed change in investment adviser to MLM will be presented in a proxy statement that will be provided to the Fund’s shareholders at a meeting of the Fund’s shareholders.

The proxy statement has yet to be filed with the SEC. After the proxy statement is filed with the SEC, it may be amended or withdrawn at any time. When available and definitive, as applicable, the Fund’s shareholders are encouraged to review the proxy statement on the SEC website at www.sec.gov or on the Fund’s website at www.alternativefundadvisors.com.

INVESTORS HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE TRANSACTION. 

Participants in the Solicitation
The AFA Asset Based Lending Fund, MLCI, MLM, AFA, and their respective directors/trustees, officers and employees and other persons may be deemed to be participants in the solicitation of proxies from the shareholders of the Fund in connection with the proposed Transaction. Information regarding the persons who may be deemed participants in such solicitation will be set forth in the proxy statement relating to the proposed transaction when it is filed with the SEC. Shareholders may obtain additional information regarding the interests of the participants in the solicitation of proxies in connection with the proposed transaction by reading the proxy statement when it becomes available.

AFA  ASSET BASED LENDING FUND DISCLOSURES

The Fund’s quarterly repurchase offer is expected to be 5% of net assets, but may range from 5% to 25% subject to approval by the Fund’s Board of Trustees. If a repurchase offer is oversubscribed, shareholders will only be able to have a portion of their shares repurchased. There is no guarantee that shareholders will be able to tender their shares when or in the amount they desire.

Investors should carefully consider the Fund’s investment objectives, risks, charges, and expenses before investing. This information is included in the Fund Prospectus which can be accessed at https://alternativefundadvisors.com or by calling 800-452-6804. Read the prospectus carefully before you invest.

An investment in the Fund involves a high degree of risk. An investment in the Fund should be viewed only as part of an overall investment program and you should invest only if you can sustain a complete loss of your principal. An investment in the Fund is subject to, among others, the following risks:

  • The Fund is a “non-diversified” management investment company registered under the Investment Company Act of 1940, as amended;
  • Shares of the Fund are not listed on any securities exchange and it is not anticipated that a secondary market for shares will develop;
  • Shares are appropriate only for those investors who can tolerate a high degree of risk and do not require a liquid investment;
  • Although the Fund will offer quarterly liquidity through a quarterly repurchase process, there is no assurance that an investor will be able to sell or otherwise liquidate all their shares tendered during a quarterly repurchase offer; and
  • The Fund’s investment in private credit companies is speculative and involves a high degree of risk, including the risk associated with leverage.

AFA Asset Based Lending Fund is distributed by Foreside Fund Services, LLC. Foreside Fund Services is not affiliated with Mount Logan Capital Inc.

Contacts:
Mount Logan Capital Inc.
650 Madison Ave, Floor 3
New York, NY 10022
mlc.ir@mountlogan.com

Andrew Berger
SM Berger & Company
andrew@smberger.com

______________________________
1 FRE is a non-GAAP financial measure that Mount Logan believes provides valuable perspective on its business results, but it should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). Estimated FRE contribution is a forward-looking statement based on management’s current expectations and assumptions. Actual results depend on a number of factors, many of which are outside Mount Logan’s control, and may differ materially from these estimates. See “Estimates and Assumptions” for additional information.

MARLBOROUGH, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) — IPG Photonics Corporation (Nasdaq: IPGP) will release its third quarter 2026 financial results before the market opens on Tuesday, November 3, 2026. The Company will hold a conference call to review these results at 10:00 a.m. ET on the same day. To access the call, please dial 877-407-6184 in the United States or 201-389-0877 internationally. A live webcast of the call will also be available and archived in the investor relations section of the Company’s website at investor.ipgphotonics.com.

About IPG Photonics Corporation

Innovation is at the heart of IPG Photonics. As a global leader in laser technology, we apply light to transform the world. From manufacturing to medical and beyond, our breakthrough laser solutions power our customers’ success and expand what’s possible. Discover more at www.ipgphotonics.com.

Contact

Eugene Fedotoff
Senior Director, Investor Relations
IPG Photonics Corporation
508-597-4713
efedotoff@ipgphotonics.com

REDWOOD CITY, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolve 308, a global Phase 3 clinical trial evaluating zoldonrasib, an investigational, RAS(ON) G12D-selective inhibitor, in combination with standard of care pembrolizumab plus chemotherapy as a first-line treatment in adult patients with metastatic RAS G12D non-squamous non-small cell lung cancer (NSCLC).

“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed encouraging preliminary antitumor activity and a favorable safety profile, providing strong clinical rationale for the Phase 3 RASolve 308 trial. This study, along with additional registrational trials underway in multiple tumor types across our pipeline of differentiated RAS(ON) inhibitors, underscores our commitment to establishing RAS(ON) inhibition as a new standard of care and backbone for treating patients with RAS-addicted cancers,” said Alan Sandler, M.D., chief development officer of Revolution Medicines.

RASolve 308 (NCT07777822) is a global, randomized, double-blind Phase 3 trial evaluating zoldonrasib in combination with pembrolizumab and platinum-based chemotherapy doublet compared with placebo in combination with pembrolizumab and platinum-based chemotherapy doublet in the treatment of adult patients with previously untreated metastatic RAS G12D non-squamous NSCLC. The primary endpoint is progression-free survival. Key secondary endpoints include overall survival, objective response rate, duration of response, safety and tolerability, and patient-reported outcomes.

About Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80%–85% of all lung cancers, with more than 229,000 people diagnosed in the U.S. each year.1,2 Despite treatment advancements, NSCLC remains a leading cause of cancer-related mortality worldwide, primarily due to its late-stage diagnosis and limited response to conventional therapies. RAS mutations are among the most common oncogenic drivers in NSCLC, occurring in approximately 30% of cases. Of those, RAS G12D mutations occur in about 4% of NSCLC cases.³

About Zoldonrasib
Zoldonrasib is an investigational, oral, RAS(ON) G12D-selective covalent, tri-complex inhibitor that binds to cyclophilin A, creating a binary complex that binds to and inhibits the active, oncogenic RAS(ON) G12D mutation. RAS G12D is the most prevalent RAS mutation, accounting for approximately 29% of all RAS-driven cancers.4 Across tumor types, approximately 61,000 new patients with RAS G12D cancers are estimated annually in the U.S., with no targeted therapy currently approved for these patients.4 Zoldonrasib is currently being investigated as a monotherapy and in combination with other therapies, including with Revolution Medicines’ RAS(ON) multi-selective inhibitor RASONQUETM (daraxonrasib), as well as standard of care regimens in lung and gastrointestinal cancers.

About Revolution Medicines, Inc.
Revolution Medicines is a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide. For more information, visit www.revmed.com and follow Revolution Medicines on LinkedIn, X (Twitter) and Instagram.

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation statements regarding the broad potential of RAS(ON) inhibition, including in lung and gastrointestinal cancers; treatment practices for lung cancer; the company’s development strategy; and progression of clinical studies and findings from these studies, including the tolerability, safety, and potential efficacy of the company’s candidates being studied.

Forward-looking statements are typically, but not always, identified by the use of words such as “aims,” “anticipate,” “believe,” “estimate,” “expect,” “plan,” “potential,” “project,” “up to,” “will” and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the company’s development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including the company’s programs’ development stages, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the company’s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the company’s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape, and the effects on the company’s business of global events, such as international conflicts or global pandemics. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 5, 2026, and its future periodic reports to be filed with the SEC. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances, or to reflect the occurrence of unanticipated events.

Revolution Medicines Media & Investor Contacts 

Media
media@revmed.com  

Investors
investors@revmed.com 

References

¹ American Cancer Society. What Is Lung Cancer? Available at: https://www.cancer.org/cancer/types/lung-cancer/about/what-is.html. Accessed August 2026.
2 American Cancer Society. Key Statistics for Lung Cancer. Available at: https://www.cancer.org/cancer/types/lung-cancer/about/key-statistics.html. Accessed August 2026.
³ Reita D, Pabst L, Pencreach E, et al. Direct targeting KRAS mutation in non-small cell lung cancer: Focus on resistance. Cancers (Basel). 2022;14(15):1321. doi:10.3390/cancers14051321
4 Estimated using tumor mutation frequencies from Foundation Medicine Insights March 2022 and scaled to estimated patient numbers using cancer incidence from ACS Cancer Facts and Figures 2023.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.